期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 5, 页码 1746-1767出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01254
关键词
-
资金
- Cancer Research UK [C2115/A21421]
- Medical Research Council [G0901526]
- Cancer Research UK [21421] Funding Source: researchfish
- Medical Research Council [G0901526, G0800014] Funding Source: researchfish
- MRC [G0901526, G0800014] Funding Source: UKRI
Purines and related heterocycles substituted at C-2 with 4'-sulfamoylanilino and at C-6 with a variety of groups have been synthesized with the aim of achieving selectivity of binding to CDK2 over CDK1. 6-Substituents that favor competitive inhibition at the ATP binding site of CDK2 were identified and typically exhibited 10-80-fold greater inhibition of CDK2 compared to CDK1. Most impressive was 44(6-([1,1'-bipheny1]-3-y1)-9H-purin-2-yl)amino) benzenesulfonamide (73) that exhibited high potency toward CDK2 (IC50 0.044 mu M) but was similar to 2000-fold less active toward CDK1 (IC50 86 mu M). This compound is therefore a useful tool for studies of cell cycle regulation. Crystal structures of inhibitor kinase complexes showed that the inhibitor stabilizes a glycine-rich loop conformation that shapes the ATP ribose binding pocket and that is preferred in CDK2 but has not been observed in CDK1. This aspect of the active site may be exploited for the design of inhibitors that distinguish between CDK1 and CDK2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据